Thema: KR7326030004
SK Biopharm, KR7326030004
stock-1863880_1920.jpg - Foto: THN
SK Biopharm stock: Q3 operating profit jumps 65.9% on U.S. sales
U.S. sales of Xcopri drove stronger quarterly revenue and operating profit. Net income declined despite the improved operating performance.
ad-hoc-news.de, heute 03:19 Uhr
SK Biopharm, KR7326030004
KRW 253.2 billion revenue forecast lands for SK Biopharm ...
Xcopri prescriptions rose 6.3 percent quarter over quarter in a Hana update on SK Biopharm stock. RISE2 targets a November restart after a partial clinical hold.
ad-hoc-news.de, 19.10.26 03:54 Uhr
SK Biopharm, KR7326030004
SK Biopharm expands global ties: what it means for SK Biopharm ...
SK Biopharm stock gets a pipeline reference from a USD 315.00 million deal. Revenue reached KRW 247.0 billion in Q2 2026.
ad-hoc-news.de, 14.10.26 02:31 Uhr
SK Bioscience, KR7326030004
SK Bioscience stock edges higher on recent earnings momentum ...
SK Bioscience stock trades moderately higher as investors digest its most recent quarterly figures from 2026 with improving revenue and margins. The shares also reflect sector ...
ad-hoc-news.de, 20.09.26 12:23 Uhr
SK Bioscience, KR7326030004
SK Bioscience stock holds steady as investors await next ...
SK Bioscience stock traded in a stable range on the Korea Exchange as of September 19 2026 while the broader Kospi index recently moved higher on chip-related buying. Recent ...
ad-hoc-news.de, 19.09.26 10:54 Uhr
SK Bioscience, KR7326030004
SK Biopharm plans independent BIO USA booth as partnerships ...
SK Biopharm is heading to BIO USA with an independent booth, signaling a sharper push for deal-making and global visibility.
ad-hoc-news.de, 16.06.26 21:48 Uhr
SK Bioscience, KR7326030004
SK Bioscience Co Ltd stock (KR7326030004): Shares in focus ...
South Korea-based SK Bioscience Co Ltd is on investors' radar after agreeing to transfer its SKYVaricella vaccine technology to Colombia in late May 2026 while the stock continues ...
ad-hoc-news.de, 01.06.26 18:35 Uhr
SK Bioscience, KR7326030004
SK Bioscience Co Ltd stock (KR7326030004): National Growth ...
SK Bioscience Co Ltd shares are in focus after reports that South Korea s National Growth Fund will provide a 300 billion won facility to support late-stage vaccine development, while investors reassess the stock ...
ad-hoc-news.de, 29.05.26 14:15 Uhr
SK Bioscience, KR7326030004
SK Bioscience Co Ltd stock (KR7326030004): vaccine maker ...
SK Bioscience Co Ltd has reported first?quarter 2025 results and updated investors on its vaccine pipeline keeping the Korean biotech on the radar of health?care focused investors ...
ad-hoc-news.de, 21.05.26 22:10 Uhr
SK Bioscience, KR7326030004
SK Bioscience Co Ltd stock (KR7326030004): 2025 revenue ...
